ArticleMolecular therapy. Methods & clinical development2019
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.
Open access · goldAbstract read
In one paragraph
Article in Molecular therapy. Methods & clinical development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
4.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 123 citations in OpenAlex.
- Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.Blood advances · 2025Trial
- CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19Molecular therapy : the journal of the American Society of Gene Therapy · 2021Trial
- Preclinical evaluation of SLC35D3-targeted CAR-T cells for tumor-selective immunotherapy.Biochemistry and biophysics reports · 2026Article
- A Drug-Gated, Modular STAb-T Immunotherapy With External Control.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy.Journal of translational medicine · 2026Article
- A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products.International journal of pharmaceutics: X · 2026Article
- Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview.American journal of hematology · 2026Review
- A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL.Molecular therapy. Advances · 2026Article
- The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis.Frontiers in immunology · 2026Article
- Impact of IL-21 on CAR T-cell manufacturing: phenotypic, metabolic, and functional outcomes.Frontiers in immunology · 2026Article
- Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Point-of-care CAR T-cell therapy: toward broader access.Blood advances · 2025Article
- T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes.Journal for immunotherapy of cancer · 2025Article
- Article
- NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity.Cancer immunology research · 2025Article
- CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target.Cancer immunology research · 2025Article
- CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.Journal for immunotherapy of cancer · 2025Article
- Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression.Nature immunology · 2025Article
- Lymph-Node Inspired Hydrogels Enhance CAR Expression and Proliferation of CAR T Cells.ACS applied materials & interfaces · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 1 country.
Maria CastellaDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Anna BoronatDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Raquel Martín-IbáñezStem Cells and Regenerative Medicine Laboratory, Production and Validation Center of Advanced Therapies (Creatio), Department of Biomedical Sciences, University of Barcelona, Casanova 143, 08036 Barcelona, Spain.
Vanina RodríguezInstitut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS, Rosselló 153, 08036 Barcelona, Spain.
Guillermo SuñéDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Miguel CaballeroDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Berta MarzalDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Lorena Pérez-AmillDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Beatriz Martín-AntonioDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Julio CastañoJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain.
Clara BuenoJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain.
Olga BalaguéDepartment of Pathology, Hospital Clínic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain.
Europa Azucena González-NavarroDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Carles Serra-PagesDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Pablo EngelDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Ramon VilellaDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Daniel Benitez-RibasDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Valentín Ortiz-MaldonadoDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Joan CidInstitut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS, Rosselló 153, 08036 Barcelona, Spain.
Jaime TaberaUnit of Advanced Therapies, Hospital Clinic de Barcelona, Blood and Tissue Bank -BST-, Passeig del Taulat, 106, 08005 Barcelona, Spain.
Josep M CanalsInstitut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS, Rosselló 153, 08036 Barcelona, Spain.
Miquel LozanoInstitut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS, Rosselló 153, 08036 Barcelona, Spain.
Tycho BaumannDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Anna VilarrodonaUnit of Advanced Therapies, Hospital Clinic de Barcelona, Blood and Tissue Bank -BST-, Passeig del Taulat, 106, 08005 Barcelona, Spain.
Esteve TriasUnit of Advanced Therapies, Hospital Clinic de Barcelona, Blood and Tissue Bank -BST-, Passeig del Taulat, 106, 08005 Barcelona, Spain.
Elías CampoInstitut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS, Rosselló 153, 08036 Barcelona, Spain.
Pablo MenendezJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain.
Álvaro Urbano-IspizuaDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Jordi YagüeDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Patricia Pérez-GalánInstitut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS, Rosselló 153, 08036 Barcelona, Spain.
Susana RivesInstitut de Recerca Pediàtrica Hospital Sant Joan de Déu, Universidad de Barcelona, Passeig de Sant Joan de Déu, 2, 08950 Esplugues de Llobregat, Barcelona, Spain.
Julio DelgadoDepartment of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Manel JuanDepartment of Immunology, CDB, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Hospital Clínic de Barcelona · ESUniversitat de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESBanc de Sang i Teixits · ESCentro de Investigación Biomédica en Red de Cáncer · ESInstituto de Salud Carlos III · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells
Indexed as
4-1BBCD19chimeric antigen receptorimmunotherapyleukemialymphomapreclinical studiesT cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.